NCT06083857 2026-03-11
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT04739358 2023-10-18
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Criterium, Inc.
Phase 1/2 Terminated
NCT01988493 2022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT02115373 2022-08-24
c-Met Second-Line Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT05439993 2022-07-05
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
Phase 1/2 Recruiting